[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510810":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":152,"collaborators":24,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":156,"sex":162,"minAge":163,"maxAge":24,"enrollmentInfo":164,"targetDuration":24,"studyType":167,"phases":168,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Metoprolol Succinate","ACTIVE_COMPARATOR","Depending on baseline type and dose of beta blocker:\n\n* 25 mg once daily (12.5 mg once daily if \\> NYHA class II)\n* 50 mg (or 25 mg) once daily\n* 100 mg (or 50 mg) once daily\n* 200 mg (or 100 mg titrated to 200 mg) once daily",[13],"Drug: Metoprolol Succinate",{"label":15,"type":10,"description":16,"interventionNames":17},"Carvedilol","Depending on baseline type and dose of beta blocker:\n\n* 3.125 mg twice daily\n* 6.25 mg twice daily\n* 12.5 mg twice daily\n* 25 mg twice daily (may titrate to 5 0mg twice daily if \\> 85 kg)",[18],"Drug: Carvedilol",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","a dialyzable, beta-1 selective beta blocker",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties",[15],[29],{"name":30,"affiliation":31,"role":32},"Areef Ishani, MD MS","Minneapolis VA Health Care System, Minneapolis, MN","STUDY_CHAIR",[34,38],{"name":35,"role":36,"phone":24,"phoneExt":24,"email":37},"Christopher M Donnelly","CONTACT","Christopher.Donnelly2@va.gov",{"name":39,"role":36,"phone":40,"phoneExt":24,"email":41},"Jade Fiotto","(617) 232-9500","Jade.Fiotto@va.gov",[43,61,73,85,97,113,128,140],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"VA Long Beach Healthcare System, Long Beach, CA","RECRUITING","Long Beach","California","90822","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-118.18923,33.76696,{"lat":55,"lon":54},[58],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":60},"Srihari Raju, MD","Srihari.Raju@va.gov",{"facility":62,"status":45,"city":63,"state":64,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"North Florida\u002FSouth Georgia Veterans Health System, Gainesville, FL","Gainesville","Florida","32608-1135",{"type":52,"coordinates":67},[68,69],-82.32483,29.65163,{"lat":69,"lon":68},[72],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":60},{"facility":74,"status":45,"city":75,"state":76,"zip":77,"country":49,"countryCode":50,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Atlanta VA Medical and Rehab Center, Decatur, GA","Decatur","Georgia","30033-4004",{"type":52,"coordinates":79},[80,81],-84.29631,33.77483,{"lat":81,"lon":80},[84],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":60},{"facility":86,"status":45,"city":87,"state":88,"zip":89,"country":49,"countryCode":50,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Iowa City VA Health Care System, Iowa City, IA","Iowa City","Iowa","52246-2292",{"type":52,"coordinates":91},[92,93],-91.53017,41.66113,{"lat":93,"lon":92},[96],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":60},{"facility":98,"status":99,"city":100,"state":101,"zip":102,"country":49,"countryCode":50,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA","NOT_YET_RECRUITING","Boston","Massachusetts","02130-4817",{"type":52,"coordinates":104},[105,106],-71.05977,42.35843,{"lat":106,"lon":105},[109],{"name":110,"role":36,"phone":111,"phoneExt":24,"email":112},"Jade Fiotto, MPH","617-232-9500","jade.fiotto@va.gov",{"facility":31,"status":45,"city":114,"state":115,"zip":116,"country":49,"countryCode":50,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Minneapolis","Minnesota","55417-2309",{"type":52,"coordinates":118},[119,120],-93.26384,44.97997,{"lat":120,"lon":119},[123,127],{"name":30,"role":36,"phone":124,"phoneExt":125,"email":126},"612-467-4431","314431","areef.ishani@va.gov",{"name":30,"role":32,"phone":24,"phoneExt":24,"email":24},{"facility":129,"status":45,"city":130,"state":131,"zip":132,"country":49,"countryCode":50,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE","Omaha","Nebraska","68105-1850",{"type":52,"coordinates":134},[135,136],-95.94043,41.25626,{"lat":136,"lon":135},[139],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":60},{"facility":141,"status":45,"city":142,"state":143,"zip":144,"country":49,"countryCode":50,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"New Mexico VA Health Care System, Albuquerque, NM","Albuquerque","New Mexico","87108-5153",{"type":52,"coordinates":146},[147,148],-106.65114,35.08449,{"lat":148,"lon":147},[151],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":60},{"type":153,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100510810","phase-3-csp-2026---beta-blocker-dialyzability-on-cardiovascular-outcomes-100510810",false,"NCT05931276","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)","BRAVO","Inclusion Criteria:\n\n* On hemodialysis\n* Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol\n\nExclusion Criteria:\n\n* Impaired decision-making capacity\n* Patients not receiving carvedilol who have a history of asthma\n* known hypersensitivity to any component of either drug\n* Provider unwilling to sign a new medication order for a randomized patient\n* No surrogate consent will be allowed","ALL","18 Years",{"count":165,"type":166},2540,"ESTIMATED","INTERVENTIONAL",[169],"PHASE3","The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.",[172,173],"End-Stage Kidney Disease","End-Stage Renal Disease",[175,176,177,178,179,9,15,180],"Dialysis","beta-Blockers, Adrenergic","Cardiovascular Diseases","Point of Care Research","Comparative Effectiveness Research","Hemodialysis","2026-01-07",{"date":183,"type":184},"2026-01-09","ACTUAL",{"date":186,"type":184},"2024-05-22",{"date":188,"type":166},"2028-12-31",{"name":5,"class":6},8]